Expanding the labeled indication to include OSA opened the door to payer-supported access to GLP-1 therapy for patients with obesity-associated OSA, with the potential to reduce reliance on devices
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
It is an aminopropyl carbazole compound and orally bioavailable, can cross the BBB, and is atoxic when the dose is several times higher than the effective dose (177)
Dordevic D, Jancikova S, Vitezova M, Kushkevych I
Doctors prescribe them to treat diabetes only when lifestyle interventions and other medications (like metformin) fail to control blood sugar
17 Its mechanism includes enhancement of glucose-dependent insulin secretion, suppression of inappropriate glucagon release, delayed gastric emptying, and reduction in food intake through appetite regulation pathways
